Cantor Fitzgerald set a $5.00 price objective on ImmunoGen, Inc. (NASDAQ:IMGN) in a research note issued to investors on Friday morning. The brokerage currently has a hold rating on the biotechnology company’s stock.

Several other research analysts have also commented on IMGN. Cowen and Company reaffirmed a hold rating on shares of ImmunoGen in a report on Saturday, May 6th. Royal Bank Of Canada set a $5.00 price target on shares of ImmunoGen and gave the company a hold rating in a report on Saturday, May 6th. Canaccord Genuity set a $6.00 price target on shares of ImmunoGen and gave the company a buy rating in a report on Saturday, May 6th. BidaskClub lowered shares of ImmunoGen from a strong-buy rating to a buy rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $6.00 price target on shares of ImmunoGen in a report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $6.76.

Shares of ImmunoGen (NASDAQ:IMGN) opened at 5.94 on Friday. The stock’s market capitalization is $517.81 million. The stock has a 50 day moving average of $6.23 and a 200-day moving average of $4.25. ImmunoGen has a one year low of $1.51 and a one year high of $8.04.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million during the quarter, compared to analyst estimates of $30.59 million. During the same period last year, the firm posted ($0.53) earnings per share. The company’s quarterly revenue was up 426.6% on a year-over-year basis. Equities analysts predict that ImmunoGen will post ($1.18) earnings per share for the current fiscal year.

WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/immunogen-inc-nasdaqimgn-given-a-5-00-price-target-at-cantor-fitzgerald/1464947.html.

Hedge funds have recently modified their holdings of the stock. Aperio Group LLC increased its stake in shares of ImmunoGen by 45.1% in the second quarter. Aperio Group LLC now owns 16,797 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 5,221 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of ImmunoGen by 2.8% in the first quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 743 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of ImmunoGen during the first quarter valued at $117,000. Parametric Portfolio Associates LLC increased its stake in shares of ImmunoGen by 7.7% in the first quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 2,753 shares in the last quarter. Finally, Stephens Inc. AR purchased a new stake in shares of ImmunoGen during the first quarter valued at $152,000. Hedge funds and other institutional investors own 73.73% of the company’s stock.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.